Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | THRB | P10828 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 5/20 | 0.60 |
| ▸ | CA2 | P00918 | 5/20 | 0.60 |
| ▸ | CA9 | Q16790 | 5/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 4/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12004705 | 0.96 | LMNA (0.64) | LMNAMAPK1ALDH1A1THRBTSHR | |
| SCHEMBL681530 | 0.86 | LMNA (0.73) | LMNAMAPK1ALDH1A1THRBTSHR | |
| SCHEMBL28927348 | 0.84 | LMNA (0.76) | LMNAMAPK1ALDH1A1THRBTSHR | |
| SCHEMBL9711175 | 0.84 | MAPK1 (0.76) | LMNAMAPK1ALDH1A1THRBTSHR | |
| SCHEMBL4470811 | 0.84 | LMNA (0.66) | LMNAMAPK1ALDH1A1THRBTSHR | |
| SCHEMBL11863715 | 0.83 | LMNA (0.69) | LMNAMAPK1ALDH1A1THRBTSHR | |
| Metronidazole SCHEMBL2670090 | 0.82 | LMNA (0.94) | LMNAMAPK1ALDH1A1THRBTSHR | |
| SCHEMBL3466681 | 0.81 | LMNA (0.62) | LMNAMAPK1ALDH1A1THRBTSHR | |
| SCHEMBL4091924 | 0.81 | LMNA (0.71) | LMNAMAPK1ALDH1A1THRBTSHR | |
| SCHEMBL11521436 | 0.81 | LMNA (0.71) | LMNAMAPK1ALDH1A1THRBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170274087-A1 | SACCHARIDE ANALOGS AND AGENTS FOR THE DIAGNOSIS AND THERAPY OF BACTERIAL INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-09-28 | — | — | US | disclosed |
| US-6255495-B1 | KILLING HYPOXIC TUMOR CELLS AND TREATING DERMATOLOGICAL DISEASES IN WARM-BLOODED ANIMALS VIA ADMINISTERING RADIOSENSITIZING AMOUNT OF ELECTRON-AFFINIC-DIAMINE | FLORIDA STATE UNIVERSITY | 2001-07-03 | — | — | US | disclosed |
| US-6060604-A | FOR RADIOTHERAPY TECHNIQUES, INCREASING TUMOR RADIOSENSITIVITY | FLORIDA STATE UNIVERSITY (US) | 2000-05-09 | — | — | US | disclosed |
| US-6057453-A | OXIDATION, FORMING RADIOSENSITIZING DIAMINES, REDUCTION | FLORIDA STATE UNIVERSITY (US) | 2000-05-02 | — | — | US | disclosed |
| CN-1232395-A | Pharmaceutical compounds containing polyamines substituted with electron affinity groups | UNIV FLORIDA STATE (US) | 1999-10-20 | — | — | CN | disclosed |
| US-4065567-A | Substituted nitroimidazolyl thiadiazoles and oxadiazoles as antibacterial agents and growth promoting compounds | AMERICAN CYANAMID COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-3991200-A | Substituted nitroimidazolyl thiadiazoles and oxadiazoles as antibacterial agents and growth promoting compounds | AMERICAN CYANAMID COMPANY (US) | 1976-11-09 | — | — | US | disclosed |
| US-3952007-A | Processes for preparing 5-nitro-1-methyl-2-(2-dialkylaminovinyl)-imidazole and 5-nitro-1-methyl-2-imidazolyl carboxaldehyde | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170274087-A1 | SACCHARIDE ANALOGS AND AGENTS FOR THE DIAGNOSIS AND THERAPY OF BACTERIAL INFECTIONS | DDOST, STT3B, CD47 | LMNA 4358/4885MAPK1 3828/4885ALDH1A1 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.